The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Regulatory Mechanisms Controlling Gene Expression Mediated by the Antioxidant Response Element
Nguyen, T., Sherratt, P. J., & Pickett, C. B. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140229 · Cited by 1,236
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Self-citationItoh, K., Tong, K. I., & Yamamoto, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.075 · Cited by 864
Self-citationMitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
Dutta, R., McDonough, J., Yin, X., Peterson, J., Chang, A., Torres, T., Gudz, T., Macklin, W. B., Lewis, D. A., Fox, R. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20736 · Cited by 841
Lee, J.-M., Calkins, M. J., Chan, K., Kan, Y. W., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211558200 · Cited by 786
Molecular mechanisms of Nrf2‐mediated antioxidant response
Li, W., & Kong, A. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20465 · Cited by 785
Kwak, M.-K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M., & Kensler, T. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211898200 · Cited by 660
Self-citationInstitute of Laboratory Animal Resources.
Wolfle, T. L. (1995) · Cited by 620
Cited by
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 790
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“Multiplex cytokine analysis in blood evidenced an increase of the anti-inflammatory cytokine IL-10 in DMF-treated animals (Schilling et al., 2006).”
BackgroundEmerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection
Zhang, M., An, C., Gao, Y., Leak, R. K., Chen, J., & Zhang, F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.09.003 · Cited by 617
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
NRF2-regulation in brain health and disease: Implication of cerebral inflammation
Sandberg, M., Patil, J., D'Angelo, B., Weber, S. G., & Mallard, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.004 · Cited by 390
The Role of Astrocytes in Multiple Sclerosis
Ponath, G., Park, C., & Pitt, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00217 · Cited by 359
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 359
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., & Wiendl, H. (2014) · Drugs · doi:10.1007/s40265-014-0212-x · Cited by 356
A metabolite-derived protein modification integrates glycolysis with KEAP1–NRF2 signalling
Bollong, M. J., Lee, G., Coukos, J. S., Yun, H., Zambaldo, C., Chang, J. W., Chin, E. N., Ahmad, I., Chatterjee, A. K., Lairson, L. L., et al. (2018) · Nature · doi:10.1038/s41586-018-0622-0 · Cited by 343
The Immune Response in Multiple Sclerosis
Rodríguez Murúa, S., Farez, M. F., & Quintana, F. J. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052920-040318 · Cited by 335
Nrf2—a therapeutic target for the treatment of neurodegenerative diseases
Johnson, D. A., & Johnson, J. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.147 · Cited by 321
Groves, A., Kihara, Y., & Chun, J. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.02.011 · Cited by 314
Shin, C.-S., Mishra, P., Watrous, J. D., Carelli, V., D’Aurelio, M., Jain, M., & Chan, D. C. (2017) · Nature Communications · doi:10.1038/ncomms15074 · Cited by 305
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 293
Self-citationNrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs
Satoh, T., McKercher, S. R., & Lipton, S. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.022 · Cited by 267
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron
Singhal, R., Mitta, S. R., Das, N. K., Kerk, S. A., Sajjakulnukit, P., Solanki, S., Andren, A., Kumar, R., Olive, K. P., Banerjee, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143691 · Cited by 215
Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells
Blewett, M. M., Xie, J., Zaro, B. W., Backus, K. M., Altman, A., Teijaro, J. R., & Cravatt, B. F. (2016) · Science Signaling · doi:10.1126/scisignal.aaf7694 · Cited by 194
“Several groups have therefore posited that the drug stimulates an antioxidant response by modifying cysteine residues in the Nrf2 (nuclear factor erythroid 2–related factor 2)–Keap1 (Kelch-like erythroid cell-derived protein with CNC homology–associated protein 1) complex, a major electrophile response pathway inmamma…”
BackgroundBell, K. F. S., Al-Mubarak, B., Martel, M.-A., McKay, S., Wheelan, N., Hasel, P., Márkus, N. M., Baxter, P., Deighton, R. F., Serio, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8066 · Cited by 191
Self-citationBrennan, M. S., Matos, M. F., Li, B., Hronowski, X., Gao, B., Juhasz, P., Rhodes, K. J., & Scannevin, R. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120254 · Cited by 188
“1) has been shown to have anti-inflammatory, cytoprotective, and immunomodulatory properties in pre-clinical models of MS [7, 8].”
BackgroundSelf-citationKeap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
The role of glial cells in multiple sclerosis disease progression
Healy, L. M., Stratton, J. A., Kuhlmann, T., & Antel, J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00624-x · Cited by 152
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Fox, R. J., Kita, M., Cohan, S. L., Henson, L. J., Zambrano, J., Scannevin, R. H., O'Gorman, J., Novas, M., Dawson, K. T., & Phillips, J. T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.849236 · Cited by 124
Self-citationdos S. Baião, D., da Silva, D. V. T., & Paschoalin, V. M. F. (2020) · Antioxidants · doi:10.3390/antiox9100960 · Cited by 102
Brennan, M. S., Matos, M. F., Richter, K. E., Li, B., & Scannevin, R. H. (2017) · Scientific Reports · doi:10.1038/srep42054 · Cited by 87
Self-citationDimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex
Zaro, B. W., Vinogradova, E. V., Lazar, D. C., Blewett, M. M., Suciu, R. M., Takaya, J., Studer, S., de la Torre, J. C., Casanova, J.-L., Cravatt, B. F., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801627 · Cited by 68
Maugeri, G., Bucolo, C., Drago, F., Rossi, S., Di Rosa, M., Imbesi, R., D’Agata, V., & Giunta, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684680 · Cited by 47
“In particular, DMF counteracted the apoptotic cascade by increasing cells survival and reducing the inflammatory process (Wilms et al., 2010; Linker et al., 2011; Scannevin et al., 2012; Wang et al., 2015).”
BackgroundDimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice
Möhle, L., Brackhan, M., Bascuñana, P., & Pahnke, J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147579 · Cited by 21
Metadata
- Authors
- Scannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., & Rhodes, K. J.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 341
- Issue
- 1
- Pages
- 274-284
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2152100400
- Cited by
- 461
- References
- 42
- FWCI
- 16.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.